Bevacizumab—a vascular endothelial growth factor inhibitor—has been shown to be effective in patients with hereditary hemorrhagic telangiectasia (HHT) and bleeding due to gastric antral vascular ectasia (GAVE) or SBA, recurring after endoscopic therapy. This evidence concerns the gene VEGFA and gastric antral vascular ectasia.